Centre has placed orders in advanced commitments for over 6 crore doses of COVID vaccine from SII and Bharat Biotech for inoculating 3 crore healthcare and frontline workers in first vaccination phase that starts January 16

A team from Precisa Medicamentos visited the Bharat Biotech's Hyderabad facility last week to discuss potential export possibilities of Covaxin with Chairman Dr Krishna Ella on the January 7-8

Among these vaccines are those developed by Zydus Cadila, Biological E and Gennova, along with Russia's Sputnik-V vaccine

The two vaccines - Covishield and Covaxin - have received regulatory approval after extensive studies. The Covishield  vaccine has already been rolled out in the UK

The first order of 1.1 crore doses will be worth Rs 231 crore, while the total amount, including the commitment for 4.5 crore doses, with the total estimated to reach Rs 1,176 crore at current rates

Pfizer is yet to submit additional data sought by India authorities regarding its COVID-19 vaccine for granting emergency use approval to it; the company has missed last three SEC meetings too

Ahead of the nationwide roll-out of COVID-19 vaccine, states have made all necessary preparations, including identifying vaccination sites and registration of healthcare and other frontline workers

This will be the first interaction between the Prime Minister and the chief ministers of all states after the Drugs Controller General of India (DCGI) granted emergency use authorisation to Covishield and Covaxin

Coronavirus vaccination drive: The letter alleged irregularities and ethical violations in the conduct of the clinical trial of Covaxin by the People's College of Medical Sciences & Research Centre, Bhopal

First phase of COVID-19 vaccination will cover 30 crore people from priority groups, including 3 crore healthcare and frontline workers, along with 27 crore people above 50 years of age and those with co-morbiditiesa

Bharat Biotech chairman Krishna Ella says this nasal vaccine will revolutionise Indian vaccine making capabilities and help it leapfrog along with Europe, the US and China

A government official said the final due diligence and certification formalities for placing bulk purchase orders were on and that the supply order was likely to be placed by Friday

COVID-19 vaccination drive: This development comes after the government said that the vaccine would be rolled out 10 days after the date of approval for emergency use

Dr Krishna Ella, Chairman of Bharat Biotech, said that unlike the clinical trials of AstraZeneca vaccine (which has been licensed to Serum Institute of India), Bharat Biotech did not try to suppress the side effects of vaccine by giving paracetamol to the volunteers. He also said that for his company safety came first. Watch him in conversation with Rajeev Dubey, Editor, Business Today.Also Read: China denies entry to WHO team investigating COVID-19 origins

The vaccine produced by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology, Pune, has courted many controversies since it began its first human trials. In this video, Bharat Biotech chief Dr Krishna Ella talks to Business Today Editor, Rajeev Dubey, about vaccine efficacy and why people get suspicious about Indian companies.

First coronavirus vaccine shots likely on January 13: Health Ministry Union Health Ministry announced on Tuesday that coronavirus vaccines will be rolled out within 10 days of granting emergency use approval based on the feedback of dry-run across the country. The announcement by the ministry comes just days after the DCGI (Drugs Controller General of India) approved Oxford-AstraZeneca COVID-19 vaccine, Covishield, domestically manufactured by the Serum Institute of India and Bharat Biotech...

(For) all our vaccines, we are looking at right now..(we) are targeting 2-8 degree because our logistics are worked out on that basis and we are working on that, DBT secretary Renu Swarup said at a press briefing

Bhopal gas activist Rachna Dhingra through a tweet on Sunday had alleged that poor and vulnerable residents of gas affected communities were herded by the People's University with a promise of Rs 750

As urbanisation and deforestation takes place, and global travel increases, viruses get the right environment to mutate and thereby grow. In such a situation how can one prepare for the future ? Watch as Dr Krishna Ella, chairman, Bharat Biotech, shares his views with Business Today editor, Rajeev Dubey.

Talking to BusinessToday.In, Dr. Krishna Ella, Chairman and MD, Bharat Biotech, said the trial would take around four months and if the regulator gives quick permission the company might start with the clinical trial